Literature DB >> 16952027

Candidates for curative resection in advanced gastric cancer patients who had equivocal para-aortic lymph node metastasis on computed tomographic scan.

Jun Ho Lee1, Yong Hae Paik, Jong Seok Lee, Ho Joon Song, Keun Won Ryu, Chan Gyoo Kim, Sook Ryeon Park, Myoung Cheorl Kook, Young Woo Kim, Jae-Moon Bae.   

Abstract

BACKGROUND: The aim of this study was to determine how to select potential candidates for curative resection among advanced gastric patients with equivocal findings of para-aortic lymph node metastasis on computed tomography (CT).
METHODS: We analyzed the clinicopathologic results of 23 advanced gastric cancer patients who were diagnosed as having equivocal findings of para-aortic lymph node metastasis on a CT scan and who underwent gastrectomy with D2 and para-aortic lymph node dissection.
RESULTS: Twenty-two patients were male, and one patient was female. The median age of all study subjects was 52 years (range, 31-75 years). Sixteen underwent total gastrectomy, and seven underwent subtotal gastrectomy. The median number of A2 (suprarenal) lymph nodes harvested was 2 (range, 1-5), and that of B1 (infrarenal) lymph nodes was 6 (range, 1-17). Ten (43.5%) of the 23 patients were proven pathologically to have metastasis to para-aortic lymph nodes. Two patients with cT2 cancer had no metastatic para-aortic lymph node, whereas three patients with cT4 disease had metastatic para-aortic lymph nodes (P = .021). Seven (70.0%) of 10 patients with pathologic para-aortic lymph node metastasis experienced recurrence, whereas only 2 (15.4%) of 13 patients without experienced recurrence (P = .008). The Lauren classification was found to be an independent predictor of para-aortic lymph node metastasis (relative risk; .13; 95% confidence interval, .02-.83; P = .03).
CONCLUSIONS: More than half of gastric cancer patients with equivocal findings of para-aortic lymph node metastasis on CT are potential candidates for curative resection. The Lauren classification of gastric cancer in patients with equivocal CT findings of para-aortic lymph node metastasis would be helpful when deciding on clinical stage and treatment plans in these patients.

Entities:  

Mesh:

Year:  2006        PMID: 16952027     DOI: 10.1245/s10434-006-9002-3

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  6 in total

1.  Application value of multi-slice spiral computed tomography for imaging determination of metastatic lymph nodes of gastric cancer.

Authors:  Chun-Lai Dai; Zhi-Gang Yang; Li-Ping Xue; Yu-Mei Li
Journal:  World J Gastroenterol       Date:  2013-09-14       Impact factor: 5.742

Review 2.  Preoperative workflow for lymph nodes staging.

Authors:  Debora Botturi; Francesca Pizzorni Ferrarese; Giulia Angela Zamboni; Davide Zerbato
Journal:  Int J Comput Assist Radiol Surg       Date:  2008-10-28       Impact factor: 2.924

Review 3.  Para-aortic lymphadenectomy in surgery for gastric cancer: current indications and future perspectives.

Authors:  Valentina Mengardo; Maria Bencivenga; Jacopo Weindelmayer; Michele Pavarana; Simone Giacopuzzi; Giovanni de Manzoni
Journal:  Updates Surg       Date:  2018-05-30

4.  Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.

Authors:  Salah-Eddin Al-Batran; Nils Homann; Claudia Pauligk; Gerald Illerhaus; Uwe M Martens; Jan Stoehlmacher; Harald Schmalenberg; Kim B Luley; Nicole Prasnikar; Matthias Egger; Stephan Probst; Helmut Messmann; Markus Moehler; Wolfgang Fischbach; Jörg T Hartmann; Frank Mayer; Heinz-Gert Höffkes; Michael Koenigsmann; Dirk Arnold; Thomas W Kraus; Kersten Grimm; Stefan Berkhoff; Stefan Post; Elke Jäger; Wolf Bechstein; Ulrich Ronellenfitsch; Stefan Mönig; Ralf D Hofheinz
Journal:  JAMA Oncol       Date:  2017-09-01       Impact factor: 31.777

5.  The RENAISSANCE (AIO-FLOT5) trial: effect of chemotherapy alone vs. chemotherapy followed by surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction - a phase III trial of the German AIO/CAO-V/CAOGI.

Authors:  Salah-Eddin Al-Batran; Thorsten O Goetze; Daniel W Mueller; Arndt Vogel; Michael Winkler; Sylvie Lorenzen; Alexander Novotny; Claudia Pauligk; Nils Homann; Thomas Jungbluth; Christoph Reissfelder; Karel Caca; Steffen Retter; Eva Horndasch; Julia Gumpp; Claus Bolling; Karl-Hermann Fuchs; Wolfgang Blau; Winfried Padberg; Michael Pohl; Andreas Wunsch; Patrick Michl; Frank Mannes; Matthias Schwarzbach; Harald Schmalenberg; Michael Hohaus; Christian Scholz; Christoph Benckert; Jorge Riera Knorrenschild; Veit Kanngießer; Thomas Zander; Hakan Alakus; Ralf-Dieter Hofheinz; Claus Roedel; Manish A Shah; Mitsuru Sasako; Dietmar Lorenz; Jakob Izbicki; Wolf O Bechstein; Hauke Lang; Stefan P Moenig
Journal:  BMC Cancer       Date:  2017-12-28       Impact factor: 4.430

Review 6.  Conversion Surgery for Stage IV Gastric Cancer.

Authors:  Fei Zhang; Xuanzhang Huang; Yongxi Song; Peng Gao; Cen Zhou; Zhexu Guo; Jinxin Shi; Zhonghua Wu; Zhenning Wang
Journal:  Front Oncol       Date:  2019-11-07       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.